Latest / The Well-Built Life / Science and Reality of Lifespan Extension: The Controversy and Prospects of PCC1
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. All right, Thomas, let's dive into
- 0:25Speaker 1: the latest developments at Lonvy Biosciences. This company has made
- 0:30Speaker 1: some significant strides with their PCC1 supplement, especially in the
- 0:34Speaker 1: realm of senescent cells. Could you give us a quick
- 0:37Speaker 1: breakdown of what PCC1 is and what it does?
- 0:40Speaker 2: Sure, Rachel. PCC1, or procyanidin C1, is a compound extracted
- 0:46Speaker 2: from grape seeds. This research started gaining traction in 2021
- 0:50Speaker 2: when a groundbreaking study was published in Nature Metabolism. It
- 0:54Speaker 2: showed that PCC1 can target senescent cells, effectively extending both
- 0:59Speaker 2: healthspan and lifespan in mice.
- 1:01Speaker 1: Right, and that's the crucial nuance here. The concept of
- 1:05Speaker 1: senescent cells, or zombie cells, is key. These cells are
- 1:10Speaker 1: essentially stalled and hard to kill, contributing to chronic inflammation
- 1:15Speaker 1: and age-related diseases. PCC1 operates in a unique way, functioning
- 1:20Speaker 1: as both a xenomorphic and senolytic agent. Sound complex? Indeed.
- 1:25Speaker 2: Its mechanism involves a dual approach. At low concentrations, PCC1
- 1:31Speaker 2: acts as a xenomorphic agent by inhibiting SASP senescent, associated
- 1:36Speaker 2: secretory phenotype signals. But in higher concentrations, it becomes senolytic,
- 1:42Speaker 2: selectively killing senescent cells. This dual mechanism is part of
- 1:46Speaker 2: what makes PCC1 so intriguing.
- 1:49Speaker 1: Exactly. Which brings up an interesting contradiction. Despite these promising findings,
- 1:56Speaker 1: Lonvy Biosciences faced a significant setback in February when Nature
- 2:00Speaker 1: Metabolism issued an expression of concern. Can you elaborate on that?
- 2:05Speaker 2: Yes. The paper had a key image that was found
- 2:08Speaker 2: to be reused without proper acknowledgement, questioning the data's integrity.
- 2:13Speaker 2: Lonvy's CTO even referenced the study as proof of extending
- 2:17Speaker 2: human lifespan to 50 years, but that's jumping the gun
- 2:20Speaker 2: given the current lack of human data. Wait.
- 2:23Speaker 1: But how does that actually play out in practice? If
- 2:27Speaker 1: the research is so promising, why is there such a
- 2:30Speaker 1: gap between theory and reality?
- 2:32Speaker 2: It's a bit of a chicken and egg scenario. The
- 2:35Speaker 2: initial focus on senolytics and xenomorphics in small studies with
- 2:39Speaker 2: age-related diseases like Alzheimer's and pulmonary fibrosis, while promising, hasn't
- 2:44Speaker 2: yet translated to clear human lifespan benefits. That said, Lanvi
- 2:49Speaker 2: Biosciences is continuing to push boundaries. But the path from
- 2:53Speaker 2: mouse to man is still a long one.
- 2:55Speaker 1: That's wild when you look at the raw numbers. They
- 2:58Speaker 1: showed a 9.4% increase in total lifespan and a 64%
- 3:03Speaker 1: increase in survival among elderly mice. But you are right.
- 3:08Speaker 1: Humans are another beast entirely. What do you make of
- 3:11Speaker 1: the industry's current stance? Are we jumping the gun?
- 3:15Speaker 2: Tyree's certainly an appeal to what Lonvy and others are selling,
- 3:19Speaker 2: but the science isn't quite there yet. The industry is
- 3:22Speaker 2: pushing the envelope with what's currently available, but we need
- 3:25Speaker 2: more robust clinical trials to back up those claims. It's
- 3:29Speaker 2: a classic case of where the buzz meets the science gap.
- 3:32Speaker 1: So let's dive into the specific mechanisms of PCC1. According
- 3:36Speaker 1: to the paper in Nature Metabolism, it operates on two fronts,
- 3:40Speaker 1: xenomorphic and senolytic. Can you give us a bit more
- 3:44Speaker 1: detail on that?
- 3:45Speaker 2: Sure. At low concentrations, PCC1 acts xenomorphically. which means it
- 3:51Speaker 2: inhibits the SASP senescence, associated secretory phenotype, signals, effectively silencing
- 3:58Speaker 2: those harmful signals without outright eliminating the senescent cells. It's
- 4:03Speaker 2: like turning down the volume on a noisy machine to
- 4:06Speaker 2: make it run smoother.
- 4:07Speaker 1: Got it. And it gets more interesting when the concentration increases.
- 4:12Speaker 1: At higher levels, PCC1 switches to a senolytic mode where
- 4:17Speaker 1: it selectively destroys senescent cells. This dual approach is pretty unique,
- 4:22Speaker 1: isn't it? It's like having a surgeon's scalpel and a balm,
- 4:26Speaker 1: hitting both the harmful and the benign aspects of cellular aging.
- 4:30Speaker 2: Exactly. It's a fine line between too much and not enough.
- 4:35Speaker 2: The key is finding that balance, and the study showed
- 4:37Speaker 2: that intermittent dosing in mice led to improved physical function
- 4:41Speaker 2: and extended survival. The 64% increase in survival among elderly
- 4:46Speaker 2: mice was quite dramatic. But we need to see these
- 4:49Speaker 2: results replicated in human subjects. Right.
- 4:52Speaker 1: And this isn't just theoretical. The research has practical implications
- 4:56Speaker 1: for age-related diseases like Alzheimer's and pulmonary fibrosis. Lonvy Biosciences
- 5:02Speaker 1: is pushing the boundaries here, but the industry as a
- 5:05Speaker 1: whole is still grappling with the science and the ethics.
- 5:08Speaker 2: Absolutely. While the initial mouse studies are promising, the jump
- 5:12Speaker 2: to humans is fraught with challenges. The recent concerns raised
- 5:16Speaker 2: about the image duplication in the Nature Metabolism paper shine
- 5:20Speaker 2: a harsh light on this. It's a reminder that every
- 5:23Speaker 2: step in this research needs to be meticulously validated.
- 5:26Speaker 1: Speaking of validation, what are some of the key questions
- 5:29Speaker 1: that still persist in this field? For instance, how do
- 5:33Speaker 1: we ensure that targeting senescent cells won't inadvertently harm other
- 5:37Speaker 1: cells that might actually be beneficial for wound healing? And
- 5:41Speaker 1: so on.
- 5:42Speaker 2: That's a great point. We are still trying to understand
- 5:45Speaker 2: which stand which senescent cells play a healthy role and
- 5:48Speaker 2: which are truly pathological. The science is evolving. But we
- 5:53Speaker 2: are not quite there yet. The goal is to develop
- 5:56Speaker 2: targeted therapies that selectively remove the bad actors without touching
- 6:00Speaker 2: the good ones. But right now, that's more of a
- 6:04Speaker 2: theoretical direction than a practical reality.
- 6:07Speaker 1: It's clear that the path ahead is complex and fraught
- 6:10Speaker 1: with challenges. But as we keep pushing the boundaries, the
- 6:14Speaker 1: hope remains that one day we might see significant improvements
- 6:18Speaker 1: in human healthspan and lifespan.
- 6:21Speaker 2: Exactly. The science is fascinating, and Therese so much more
- 6:25Speaker 2: to explore. For now, the conversation turns to more human
- 6:29Speaker 2: trials and real-world applications. But for the researchers, the journey
- 6:34Speaker 2: to uncover the mechanisms of PCC1 and other senolytics is
- 6:39Speaker 2: just beginning.
- 6:40Speaker 1: This all sounds promising, Thomas, but to raise a caveat,
- 6:44Speaker 1: how do we reconcile the initial hype with the reality
- 6:47Speaker 1: of the current state of research and clinical trials?
- 6:50Speaker 2: You hit the nail on the head, Rachel. The tension
- 6:52Speaker 2: between the potential benefits highlighted in preclinical studies and the
- 6:56Speaker 2: practical application in humans is stark. Take, for instance, the
- 7:01Speaker 2: expression of concern published in Nature Metabolism. It questions the
- 7:05Speaker 2: integrity of the data used to support PCC1' s claims.
- 7:10Speaker 1: Exactly. That's the first major contradiction. The original studies seemed
- 7:15Speaker 1: so compelling, but then they are suddenly under scrutiny. How
- 7:19Speaker 1: does this impact public perception and trust in PCC1?
- 7:23Speaker 2: It's a double-edged sword. On one hand, it raises the
- 7:27Speaker 2: bar for scientific rigor and transparency. which is crucial for
- 7:31Speaker 2: any potential breakthrough. On the other, it might dampen excitement
- 7:35Speaker 2: and delay the necessary funding and support. Right.
- 7:38Speaker 1: But now, the scientific community is also grappling with another challenge.
- 7:43Speaker 1: How do we target senescent cells without affecting their beneficial functions?
- 7:47Speaker 1: It's a complex ethical and physiological question.
- 7:50Speaker 2: That's the crux of the matter. The benefits of removing
- 7:53Speaker 2: senescent cells can't be fully realized if it also interferes
- 7:57Speaker 2: with necessary functions. The balance between harm and benefit is
- 8:01Speaker 2: delicate and hasn't been fully defined yet.
- 8:04Speaker 1: And let's not forget the commercial angle. Companies like Lonvy
- 8:09Speaker 1: Biosciences are pushing the PCC1 narrative hard, even though the
- 8:14Speaker 1: human data is scant. It's a fine line they are walking,
- 8:18Speaker 1: potentially creating unrealistic expectations.
- 8:21Speaker 2: Exactly. They are using the mouse model results to market
- 8:25Speaker 2: PCC1 as a potential longevity supplement. even though their own
- 8:30Speaker 2: chief technology officer acknowledges the lack of human data supporting
- 8:33Speaker 2: a 150-year life extension claim. This raises ethical questions about
- 8:39Speaker 2: marketing practices.
- 8:40Speaker 1: It's a complex web of contradictions and uncertainties. But moving forward,
- 8:45Speaker 1: what needs to be the next step for researchers to
- 8:48Speaker 1: address these concerns and challenges?
- 8:51Speaker 2: First, rigorous human trials are essential. Without robust data from
- 8:55Speaker 2: clinical studies, it's hard to make strong claims. Second, better
- 9:00Speaker 2: understanding of senescent cells themselves is needed, not just their
- 9:04Speaker 2: detrimental effects but their roles in healing and regeneration. And lastly,
- 9:09Speaker 2: clearer guidance on what metrics and measures should be used
- 9:12Speaker 2: to assess the impact of senolytic compounds.
- 9:15Speaker 1: Agreed. The road ahead is fraught with challenges, but with
- 9:19Speaker 1: careful research and transparent communication, we can mitigate some of
- 9:22Speaker 1: these controversies. And who knows, maybe we will see real breakthroughs,
- 9:28Speaker 1: that make people's later years healthier and more fulfilling.
- 9:31Speaker 2: Indeed, the journey to extending healthspan and lifespan is just beginning,
- 9:36Speaker 2: and we are all part of this collective effort to
- 9:38Speaker 2: uncover more about the mechanisms of aging.
- 9:40Speaker 1: So turning to the practical applications, Thomas, can you dive
- 9:45Speaker 1: into the clinical trials that are currently underway and the
- 9:47Speaker 1: challenges they face? We have heard a lot about how
- 9:50Speaker 1: PCC1 has shown promise in mice, but let's talk about
- 9:54Speaker 1: how it translates to humans.
- 9:56Speaker 2: Absolutely, Rachel. The first hurdle is that while peace appeared
- 10:01Speaker 2: to extend the life and health of mice, translating that
- 10:04Speaker 2: to human trials is a whole different ballgame. Ethical concerns
- 10:08Speaker 2: and practical limitations of testing longevity in humans mean that
- 10:13Speaker 2: we only have a few safety and efficacy studies for
- 10:16Speaker 2: senolytic compounds so far.
- 10:17Speaker 1: Such as? Can you give us a specific example?
- 10:21Speaker 2: Sure. Take the dasitinib and quercetin studies. Both these drugs
- 10:26Speaker 2: showed some effect in slowing aging processes in animals, but
- 10:30Speaker 2: we still lack that direct proof in humans. And PCC1
- 10:34Speaker 2: as human trials are no more advanced, with none directly
- 10:37Speaker 2: assessing its impact on lifespan.
- 10:39Speaker 1: Indeed, but let's get to the root of the issue.
- 10:42Speaker 1: Isn't the real challenge the ethical concerns? I mean, isn't
- 10:46Speaker 1: it difficult to conduct studies? that would follow people for, say,
- 10:50Speaker 1: 20 years to see changes in their lifespan? Exactly.
- 10:54Speaker 2: Ethical concerns aside, to raise the issue of scaling, we
- 10:59Speaker 2: are looking at a treatment that might extend someone's life
- 11:02Speaker 2: by years, but how do you ethically justify long-term trials
- 11:06Speaker 2: when the potential benefits are so uncertain? Plus, there are
- 11:10Speaker 2: economic implications to consider.
- 11:12Speaker 1: That's a good point. Moving on. What about the strategies
- 11:16Speaker 1: for targeting senescent cells precisely? You mentioned that researchers haven't
- 11:20Speaker 1: fully figured out which cells to target and which to
- 11:23Speaker 1: leave alone. How does that fit into the current application
- 11:26Speaker 1: and challenges of PCC1?
- 11:28Speaker 2: Precisely. The challenge lies in the specificity of the target.
- 11:32Speaker 2: Senescent cells contribute to both health and disease. Some can
- 11:36Speaker 2: be beneficial, while others cause harm. The current methods, including PCC1,
- 11:41Speaker 2: are too broad. We need a more nuanced approach that
- 11:44Speaker 2: can distinguish harmful from beneficial senescent cells.
- 11:47Speaker 1: That sounds like a tricky balance to strike. And what
- 11:49Speaker 1: about the regulatory challenges? I mean, if a company like
- 11:53Speaker 1: Lanvi Biosciences starts making bold claims, how do regulators handle that?
- 11:59Speaker 2: True. It's a fine line. Companies can't rush to market
- 12:02Speaker 2: with unverified claims. But at the same time, the regulatory
- 12:06Speaker 2: bodies are still learning and adapting to this new terrain.
- 12:10Speaker 2: to raise a risk of under-regulation, allowing false hopes to flourish,
- 12:14Speaker 2: but over-regulation might stifle innovation. It's a tricky balance.
- 12:18Speaker 1: Yes, very tricky. And in conclusion, what do you think
- 12:22Speaker 1: the future holds for PCC1 and similar treatments? Do you
- 12:27Speaker 1: see us making significant progress in this area, or are
- 12:30Speaker 1: we in for a long wait?
- 12:31Speaker 2: I hope for significant progress, Rachel. The science is there,
- 12:35Speaker 2: but it's a painstaking process. We need more longitudinal studies-
- 12:39Speaker 2: and a better understanding of senescent cells before we can
- 12:42Speaker 2: make bold claims. Yet, every breakthrough, whether in mice or
- 12:46Speaker 2: in small human studies, brings us closer to a clearer picture.
- 12:49Speaker 1: So, Thomas, what do you think about the broader implications
- 12:53Speaker 1: of targeting senescent cells for human healthspan and potentially lifespan?
- 12:58Speaker 1: It's one thing to see the results in mice, but
- 13:01Speaker 1: the practicalities are quite another.
- 13:03Speaker 2: Indeed, Rachel. The science is moving in interesting directions, but
- 13:07Speaker 2: there are many open questions. For instance, how can we
- 13:11Speaker 2: ensure that targeting senescent cells in humans won't have unintended consequences,
- 13:16Speaker 2: like disrupting the beneficial effects of certain senescent cells that
- 13:19Speaker 2: might actually aid in wound healing or tissue remodeling? Right.
- 13:23Speaker 1: And that's the crucial nuance here. The balance between senolytic
- 13:27Speaker 1: and xenomorphic approaches is delicate. What about the economic incentives
- 13:32Speaker 1: driving this research? Pharmaceutical companies are increasingly looking at longevity
- 13:37Speaker 1: as a viable new market. Does this pose a risk
- 13:40Speaker 1: of over-medicalizing aging?
- 13:42Speaker 2: Absolutely, it does. The incentive to develop quick, profitable solutions
- 13:47Speaker 2: can overshadow the need for cautious, phased approaches. This is
- 13:51Speaker 2: where regulatory bodies need to step in with clear guidelines
- 13:54Speaker 2: to prevent a rush to market that might compromise safety
- 13:57Speaker 2: and efficacy.
- 13:58Speaker 1: Exactly, which brings up an interesting contradiction. On one hand,
- 14:03Speaker 1: we want rapid advancements. but on the other, we don't
- 14:06Speaker 1: want to rush into something that could have unforeseen negative impacts.
- 14:10Speaker 1: It's a fine line, especially when we are talking about
- 14:13Speaker 1: potentially extending human life.
- 14:15Speaker 2: That's wild when you look at the raw numbers. The
- 14:18Speaker 2: potential market for anti-aging products is massive. Already, companies are
- 14:23Speaker 2: positioning themselves to ride this wave. But as we have
- 14:26Speaker 2: seen with PCC-1 and other compounds, The journey from lab
- 14:30Speaker 2: to reality is fraught with challenges.
- 14:32Speaker 1: True, and trees a broader societal question here too. As
- 14:36Speaker 1: these technologies evolve, how do we ensure they are accessible
- 14:40Speaker 1: to everyone, not just the wealthy? The ethical dimensions are profound.
- 14:45Speaker 1: We are looking at a future where extending health span
- 14:48Speaker 1: and life span becomes a potential class divide.
- 14:51Speaker 2: Absolutely. The ethical considerations are complex. If we are going
- 14:55Speaker 2: to talk about extending human life span, we need to
- 14:58Speaker 2: consider not just the biomedical aspects, but the social, economic,
- 15:02Speaker 2: and political implications as well. It's a multidisciplinary issue that
- 15:06Speaker 2: goes beyond the scope of just scientists and doctors.
- 15:09Speaker 1: And that brings us back to the core of our discussion.
- 15:12Speaker 1: While the science shows promise, the path to practical applications
- 15:16Speaker 1: is fraught with challenges. We need more longitudinal studies and
- 15:20Speaker 1: a better understanding of the nuanced roles.
- 15:24Speaker 2: In the meantime, it's essential to keep the conversation open
- 15:28Speaker 2: and critical. We need to support and fund robust research
- 15:32Speaker 2: while ensuring that the promises are tempered with reality. That way,
- 15:37Speaker 2: the scientific advancements can truly benefit everyone.
- 15:40Speaker 1: That brings us to the end of today's episode. Thank
- 15:43Speaker 1: you so much for spending part of your day with me.
- 15:46Speaker 1: If you found this episode's tips helpful and want to
- 15:49Speaker 1: make sure you don't miss the next conversation, please take
- 15:52Speaker 1: a quick second to hit that subscribe or follow button
- 15:55Speaker 1: on whatever platform you are listening on. It's a completely
- 15:59Speaker 1: free way to support the show and helps more people
- 16:02Speaker 1: find us. This podcast is independently produced, so if you
- 16:05Speaker 1: are ever in a position where you would like to
- 16:07Speaker 1: help keep it running, we do accept small donations. You
- 16:11Speaker 1: can find a link right in the episode description below
- 16:14Speaker 1: to buy us a coffee or contribute what you can.
- 16:17Speaker 1: Every bit genuinely helps. Take care of yourself. Stay balanced.
- 16:21Speaker 1: And we will talk again soon.